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Barriers and facilitators of adjuvant hormone 
therapy adherence and persistence in women 
with breast cancer: a systematic review
Zoe Moon
Rona Moss-Morris
Myra S Hunter
Sophie Carlisle
Lyndsay D Hughes
Health Psychology Section, 
Department of Psychology, 
institute of Psychiatry, Psychology &  
Neuroscience, King’s College 
London, London, UK
Purpose: Nonadherence to hormone therapy in breast cancer survivors is common and associated 
with increased risk of mortality. Consistent predictors of nonadherence and nonpersistence are 
yet to be identified, and little research has examined psychosocial factors that may be amenable 
to change through intervention. This review aimed to identify predictors of nonadherence and 
nonpersistence to hormone therapy in breast cancer survivors in order to inform development 
of an intervention to increase adherence rates.
Methods: Studies published up to April 2016 were identified through MEDLINE, Embase, 
Web of Science, PsycINFO, CINAHL and gray literature. Studies published in English measur-
ing associations between adherence or persistence and any predictor variables were included. 
Eligible studies were assessed for methodological quality, data were extracted and a narrative 
synthesis was conducted.
Results: Sixty-one eligible articles were identified. Most studies focused on clinical and demo-
graphic factors with inconsistent results. Some evidence suggested that receiving specialist care 
and social support were related to increased persistence, younger age and increased number of 
hospitalizations were associated with nonadherence, and good patient–physician relationship 
and self-efficacy for taking medication were associated with better adherence. A small amount 
of evidence suggested that medication beliefs were associated with adherence, but more high-
quality research is needed to confirm this.
Conclusion: Some psychosocial variables were associated with better adherence and persis-
tence, but the results are currently tentative. Future high-quality research should be carried out 
to identify psychosocial determinants of nonadherence or nonpersistence that are modifiable 
through intervention.
Keywords: breast cancer, adherence, persistence, hormone therapy
Introduction
Breast cancer is the most common cancer in the UK, with 150 women being diagnosed 
every day.1 Three quarters of breast cancers contain receptors for estrogen and are 
known as estrogen receptor positive (ER+). While breast cancer survival rates are 
increasing, it is still the second most common cause of death from cancer in women.1 
To increase survival rates and reduce the risk of recurrence, many women with ER+ 
breast cancer are prescribed hormone therapy (HT), such as tamoxifen, or aromatase 
inhibitors (AIs), which block the effects of estrogen on cancer cells. Five to ten years of 
HT significantly reduces rates of cancer recurrence and mortality in women with ER+ 
early breast cancer.2,3 Despite significant clinical benefits, many women do not take HT as 
prescribed, which leads to a significantly increased risk of mortality and recurrence.4–6
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Adherence to tamoxifen and AIs ranges from 65% 
to 79% and 72% to 80%, respectively, but falls over the 
course of treatment to ~50% by the fourth or fifth year.7–9 
Furthermore, half of patients discontinue HT by 5 years,10,11 
suggesting that a significant proportion of patients are not 
receiving the full clinical benefits of HT. An understanding 
of the mechanisms behind nonadherence would facilitate 
development of effective interventions, with a view to 
improving adherence and ultimately increasing the survival 
benefits associated with HT. Clinical and demographic 
factors may be useful as identifiable risk factors but cannot 
be modified through intervention. Psychosocial factors, 
however, are typically modifiable and are highly suitable 
targets for intervention. For example, illness and medica-
tion perceptions, such as necessity and concern beliefs, are 
predictive of adherence in other illnesses12,13 and have been 
successfully modified.14,15
A previous review of HT adherence and persistence 
concluded that little was known about the impact of clinical, 
demographic, or psychological factors and highlighted a 
need to research modifiable factors.16 A significant amount 
of research has been published since 2012, warranting an up-
to-date review. In 2015, Cahir et al17 carried out a systematic 
review of modifiable determinants of adherence with a 
view to developing behavioral interventions. Although the 
review was useful, there were several limitations, which are 
addressed by the current review. First, the main conclusions 
were that side effects, the number of prescription medica-
tions and the type of practitioner (general practitioner [GP] 
vs oncologist) influenced HT adherence or persistence. These 
factors are mostly not suitable for behavior change interven-
tion. A more targeted review of modifiable psychosocial pre-
dictors would provide further guidance for the development 
of an intervention. Second, as gray literature databases and 
conference abstracts were not included in the search, some 
key studies are missing from Cahir et al’s review. Finally, 
the authors conducted a meta-analysis, but due to significant 
heterogeneity, only a very small proportion of studies could 
be included, limiting the value of the results. For example, 
although 13 studies investigated the effects of the number 
of prescription medications, only four studies were eligible 
for the meta-analysis. Therefore, a narrative synthesis may 
be more appropriate. Van Liew et al18 conducted a narrative 
synthesis concluding that social support, patient-centered 
interactions, anxiety and medication beliefs were reliably 
associated with adherence or persistence. However, this 
review conducted a limited search of only two databases 
and may have missed some important eligible studies. Fur-
thermore, empirical interest in this area is growing and a 
considerable number of studies have been published in the 
2 years since the previous reviews.
The current review aims to build upon and address 
limitations in the previous reviews and identify factors related 
to HT adherence or persistence by:
(1) conducting an updated and broader search to ensure that 
all relevant articles are identified;
(2) searching gray literature databases to identify unpublished 
literature;
(3) combining modifiable psychosocial factors with demo-
graphic, clinical and health care factors to provide a com-
prehensive overview of nonadherence and nonpersistence 
in this population; and
(4) conducting a narrative synthesis as opposed to a meta-
analysis, due to the anticipated significant heterogeneity 
within the included studies.
Methods
Search strategy
The review was conducted in accordance with PRISMA 
guidelines.19 The following databases were searched from 
inception to April 2016: MEDLINE, Embase, Web of 
Science; PsycINFO and CINAHL. Search terms included 
a combination of terms related to, 1) breast cancer, 2) non-
adherence or nonpersistence, and 3) HT. Specific search 
terms are listed in Table S1. Reference lists of included 
articles were screened, and gray literature databases were 
searched.
Study selection
Inclusion/exclusion criteria are shown in Table 1. Participants 
had to be female, .18 years of age and prescribed adjuvant 
HT for primary breast cancer. Studies had to be conducted 
in clinical practice, as adherence rates are often higher in 
clinical trials.20 After removing duplicates, one author (ZM) 
Table 1 inclusion and exclusion criteria for studies in the review
Inclusion criteria Exclusion criteria
Patients were all female and 
aged .18 years
Articles not in the english language or 
where the full text was not available
Patients had been prescribed 
adjuvant HT to treat 
primary breast cancer
Studies including only DCiS or 
stage iv patients
Studies using an intervention to 
improve adherence
Studies investigating initiation to HT
Studies not providing primary data 
Studies had to be conducted 
in clinical practice
Studies had to present 
statistical tests of association 
between HT adherence or 
persistence and a correlate 
or predictor
Abbreviations: DCiS, ductal carcinoma in situ; HT, hormone therapy.
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screened titles and abstracts and excluded irrelevant articles. 
Full texts were then screened for inclusion by two authors 
(ZM and SC) using a predefined screening table, and one 
disagreement was resolved. Authors of conference abstracts 
were contacted to identify unpublished articles, and two 
authors responded with the full-text articles.
Data extraction
Information was extracted on study design, participant 
characteristics, adherence measurement, outcome measures 
and study results. Data were extracted by one researcher. 
Another researcher independently extracted data from 10% 
of articles, and there were no disagreements.
Quality assessment (QA)
The QA tool was adapted from Pasma et al21 based on recom-
mendations from Sanderson et al.22 Studies were assessed on 
methods for selecting study participants and measuring study 
variables, appropriate statistical analyses, loss to follow-up 
and removal of nonpatient-initiated nonadherence (eg, due to 
contraindications). Studies scored 1 if they met each criterion 
and 0 if it was not met or was unclear. The proportion of 
criteria met was indicated by a percentage, as some criteria 
were not applicable for all articles. One author (ZM) con-
ducted QA, and another author (SC) verified a random subset 
of 10% of articles. An additional author (LDH) resolved 
one discrepancy.
Results
A total of 6,140 articles were identified, and after removing 
duplicates and screening titles and abstracts, 120 full-text 
articles were screened. Sixty-one articles were included in the 
review (Figure 1). There was heterogeneity between studies 
in terms of outcome measures, type of effect sizes, defini-
tions of adherence and predictor variables. It is, therefore, 
inappropriate to conduct a meta-analysis.
Characteristics of studies
The majority of studies were conducted in North America 
(n=34) and Europe (n=17; Table 2). The mean sample size 
was 3,042 (range 82–26,179), and there were 181,793 
unique participants. Two studies included data analyzed 
Figure 1 Flow diagram showing results of search strategy.
Abbreviations: HT, hormone therapy; SSRN, social science research network. 
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from the same sample.23,24 One study was a follow-up 
analysis25 using the same sample as a previous study.26 All 
studies were included in the review. Studies were cross-
sectional (n=16), retrospective (n=32) and longitudinal 
(n=13). Average follow-up for retrospective and longitudinal 
studies was 3.1 years (SD =1.4) and 2.7 years (SD =1.4), 
respectively. Twelve studies included patients prescribed 
tamoxifen, seven studies included patients prescribed 
AIs and 42 studies included patients on either therapy. 
Studies measured nonadherence (n=25), discontinuation/
nonpersistence (n=29), or both (n=6). One study measured 
interruption, defined as a 60-day gap in treatment. Mea-
surements included Medication Event Monitoring System 
(MEMS; n=2), medical records (n=4), prescription records 
(n=27), self-report (n=21) and a combination of measures 
(n=7). Of the studies using self-report, only six studies used 
validated measures. Nonpersistence was defined as gaps in 
treatment of 45 days (n=3), 60 days (n=8), 90 days (n=2) and 
180 days (n=6).
Risk of bias in included studies
The average quality score was 74%, ranging from 33% to 
100% (Table 3). The majority of studies were of moderate 
quality, but there were eleven low- (#50%) and 22 high-
quality ($80%) studies. Several studies using self-report data 
had a risk of selection bias, and some studies failed to use 
validated measures (Table 3). Only one-third of the studies 
removed women from analysis who had had a recurrence or 
died and, therefore, were no longer prescribed HT.
Summary of results
The percentage of women categorized as adherent ranged 
from 47% to 97% (mean =74%, SD =13%) and fell from an 
Table 3 Quality assessment
References A B C D E F G H I Percentage
Aiello Bowles et al51 1 1 1 1 0 1 1 0 n/a 75
Barron et al54 0 1 1 1 1 1 1 0 1 78
Bender et al40 1 0 1 1 0 1 1 0 0 56
Bhatta et al61 1 1 0 0 1 0 1 0 n/a 50
Brito et al23 1 1 1 1 1 1 1 0 0 78
Brito et al24 1 1 1 1 1 1 1 0 1 89
Cheung et al90 1 1 1 1 1 1 1 1 1 100
Cluze et al10 1 0 1 0 1 1 1 1 1 78
Corter46 1 1 0 1 1 1 1 0 1 78
Danilak and 
Chambers91
1 1 1 1 1 1 1 0 1 89
Demissie et al47 1 1 0 1 1 1 1 1 0 78
Fink et al26 1 0 1 0 1 1 1 0 1 67
Font et al38 1 1 1 1 1 1 1 1 0 89
Friese et al55 1 1 0 1 1 1 1 1 1 89
Grunfeld et al66 0 0 1 1 0 0 1 0 n/a 38
Guth et al53 1 1 0 1 1 1 1 1 1 89
Hadji et al43 1 1 1 1 1 1 1 0 0 78
He et al62 1 1 1 1 1 1 1 1 1 100
Hershman et al8 1 1 1 1 1 1 1 1 1 100
(Continued)
Table 3 (Continued)
References A B C D E F G H I Percentage
Hershman et al30 0 1 1 1 1 1 1 0 0 67
Hershman et al31 1 1 1 1 1 1 1 0 1 89
Hsieh et al39 1 1 1 1 1 1 1 0 1 89
Huiart et al70 1 1 1 1 1 1 1 1 1 100
Huiart et al7 1 1 1 1 1 1 1 1 0 89
Jacob Arriola et al67 1 0 1 1 1 1 1 1 0 78
Kahn et al48 1 0 0 0 1 1 1 1 n/a 63
Karmakar69 1 0 1 1 0 1 1 1 n/a 75
Kemp et al49 1 1 1 1 1 1 1 1 1 100
Kimmick et al92 1 1 1 1 1 1 1 0 1 89
Kimmick et al27 1 1 1 1 1 1 1 0 1 89
Kostev et al45 1 1 0 1 1 1 1 0 0 67
Kostev et al44 0 1 0 1 1 1 1 0 0 56
Krotneva et al56 0 1 1 1 1 1 1 0 0 66
Kuba et al93 1 1 0 1 0 0 1 0 0 44
Lash et al25 1 0 0 0 1 1 1 0 0 44
Lee et al33 1 1 1 1 1 1 1 1 1 100
Liu et al50 1 0 0 1 1 0 1 0 0 44
Livaudais et al94 1 1 0 1 1 1 1 0 n/a 75
Llarena et al65 1 1 1 1 1 1 1 1 n/a 100
Nekhlyudov et al57 1 1 1 1 1 1 1 0 0 78
Neugut et al32 1 1 1 1 1 1 1 1 1 100
Owusu et al11 1 1 0 1 1 1 1 1 0 78
Partridge et al9 1 1 1 1 1 1 1 1 1 100
Riley et al52 1 1 1 1 1 1 1 0 0 78
Schmidt et al60 1 1 0 1 1 1 1 0 0 67
Schover et al42 0 1 0 1 0 1 0 0 n/a 38
Sedjo and Devine34 1 1 1 1 1 1 1 0 0 78
Seneviratne et al59 1 1 1 1 1 1 1 0 0 78
Sheppard et al64 1 1 0 1 1 1 1 1 0 78
Simon et al95 1 0 1 1 1 1 1 0 n/a 75
Stanton et al35 1 0 1 1 1 1 1 0 n/a 75
Tinari et al28 0 1 0 0 1 1 1 0 n/a 50
Trabulsi et al36 1 1 1 1 1 1 1 1 0 89
van Herk-Sukel 
et al63
1 1 1 1 1 1 1 1 1 100
walker et al68 1 0 1 0 0 1 0 1 n/a 50 
wickersham et al41 1 0 1 1 1 1 1 0 0 67
wigertz et al37 1 1 1 1 1 1 1 0 1 89
wouters et al29 0 0 1 0 1 1 1 0 n/a 50
wu et al58 1 1 1 1 1 1 1 0 0 78
Ziller et al96 1 0 1 1 0 1 0 0 0 44
Zeeneldin et al97 1 0 0 1 0 0 1 0 n/a 38
Notes: A: Are the main features of the study population described? B: is 
participation .80% or 60%–80% with no difference between responders and 
nonresponders? C: is adherence measured appropriately and clearly described? D: 
Are other outcome variables measured appropriately? e: Did the analysis control 
for confounding? F: Are quantitative measures of association presented? G: was 
the number of cases in the multivariate analysis at least ten times the number 
of independent variables in the final model? H: Was physician recommended 
nonadherence removed? i: were losses of patients to follow-up taken into account?
Abbreviation: n/a, not applicable.
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average of 79% in the first year of treatment to 56% in the 
fourth or fifth year. Studies using MEMS found the highest 
adherence rate (93%), followed by self-report (82%) and 
prescription refill rates (75%). Unintentional nonadherence 
(eg, forgetting) was specifically measured in three studies and 
was found to be more common than intentional nonadher-
ence (mean =31% vs 15%).27–29 Discontinuation ranged from 
9% to 63% (mean =30%, SD =12%). Discontinuation rose 
from an average of 21% in the first year to 48% in the fifth 
year. Rates of discontinuation were similar across different 
measurements (prescription refill, self-report and medical 
records). In some studies, nonpersistence and nonadherence 
are clearly separated, making it possible to combine the non-
persistence rates (23%–32%) with the nonadherence rates 
(9%–28%) to calculate the total proportion of the original 
sample who are not taking their medication as prescribed. 
In these studies, this amounts to 33%–50% across 2–4 years 
of treatment, which highlights the extent of the problem of 
nonadherence in this population.8,30–32 However, it is not 
possible to calculate this from other studies due to measure-
ment and classification issues. For example, many studies 
provide nonadherence figures (using self-report, MEMS 
and prescription refill) without being explicit as to whether 
nonpersistent women were removed from analysis or were 
classed as nonadherent. Others stated that those who discon-
tinued were removed from analysis but have not provided 
discontinuation rates. Finally, some authors have classed 
participants who discontinued treatment as nonadherent and 
some have allowed participants to be both nonpersistent and 
nonadherent. Therefore, accurate estimates of nonadherence 
and nonpersistence rates are currently lacking.
Correlates of adherence and persistence
A large number of variables showed no significant rela-
tionship with HT adherence or persistence (Table 4). The 
remaining factors are discussed later. For the purpose of 
synthesizing results, variables have been classed as having a 
positive effect, a negative effect, or no effect on adherence/
persistence. A positive/negative effect indicates a statistically 
significant relationship (P,0.05) between adherence or 
persistence and the predictor variable.
Clinical factors
Adherence
The majority of clinical factors showed no consistent asso-
ciations with adherence or showed mixed results (eg, tumor 
size, previous chemotherapy and lymph node status). Switch-
ing between HTs was associated with decreased adherence 
in seven studies23,28,33–37 and increased adherence in three 
studies.8,38,39 The majority of articles did not specify the 
direction of switching between medications.
Regarding overall side effects, two studies showed a 
negative relationship with adherence27,29 and three studies 
found no significant effects (Table 5). Hot flushes/vasomotor 
symptoms, incontinence, gastrointestinal symptoms and 
sex-related symptoms were not associated with adherence, 
whereas weight concerns were associated with decreased 
odds of adherence.40,41 Cognitive, gynecological, musculo-
skeletal and sleep/fatigue-related symptoms were associated 
with lower odds of adherence in some studies, but the effects 
were not consistently found.40–42
Persistence
Similar to adherence, the majority of clinical factors were 
not reliably associated with persistence for the prescribed 
treatment duration. Three studies found that a codiagno-
sis of osteoporosis or diabetes was related to increased 
persistence.43–45 However, mixed results were found for the 
effects of comorbidities in general, with the majority of 
studies finding no significant associations.
Five studies found that experiencing any/severe side effects 
was associated with decreased odds of persistence,25,35,46–48 but 
three studies found no significant effects. Women who expe-
rienced menopause-related side effects were up to three times 
less likely to persist10,49,50 in three studies but more likely to 
persist with treatment in two studies.48,51 Hair thinning was 
associated with increased odds of persistence, but headaches 
and loss of appetite showed the opposite effect.51 Gyneco-
logical symptoms were associated with increased odds of 
persistence in one study,51 but another two studies found no 
significant effects.
Health care factors
Adherence
Consultations with an oncologist or mastologist increased 
odds of adherence in two studies compared to women without 
these consultations.9,23 Experiencing more hospitalizations 
was associated with lower odds of adherence.9,23,34,36 Higher 
monthly prescription costs were associated with decreased 
odds of adherence in four studies,30,32,34,52 but two studies 
found no significant effects.
Persistence
Five studies showed that odds of persistence increased by 
21%–66% if treatment was received by an oncologist or a 
gynecologist as opposed to a general practitioner,32,43–45,53 
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while two studies found no significant effect. Five studies 
found that being prescribed more medications per month 
was associated with increased odds of persistence;7,25,26,54,55 
however, an additional study showed the opposite effect32 and 
three studies found no significant effects. Furthermore, two 
of the studies showing a positive effect used the same sample 
at different time points.25,26 Three studies found that women 
who were hospitalized more were less likely to persist with 
treatment,24,56,57 but one study found no significant effects. 
Women who used complementary or alternative therapies 
had lower odds of persistence.7
Demographic factors
Adherence
Nine studies showed lower odds of adherence for women 
under the age of 40/50 years,9,23,28,31,33,34,38,39,58 one study found 
the opposite,59 and three studies showed no significant effects. 
Six studies found that older women (.65/75 years) were less 
likely to be adherent.9,30–33,59 However, two studies found the 
opposite effect28,60 and six studies found no effects. Four studies 
found that being black was associated with lower odds of 
adherence than being white,8,31,32,52 but a further three studies 
found no significant effects for this relationship.30,58,61
Persistence
There was a trend suggesting that younger (,45/50 years) 
women had lower odds of persistence,8,24,43,45,54,60,62 but this was 
not always supported. Nine studies showed that older women 
were less likely to persist with treatment,8,11,30,32,48,54,57,62,63 
but seven studies found no significant association and one 
study found the opposite effect.49
Psychosocial factors
The following variables showed significant effects on adher-
ence but were only tested in one study: illness coherence46 
and self-efficacy regarding learning about medication29 
(positive effect on adherence) and practical problems associ-
ated with medication taking29 (negative effect on adherence). 
Optimism showed a positive effect on persistence,64 and 
expressing a future desire for fertility had a negative effect 
on persistence.65
Adherence
There was some evidence suggesting that medication 
beliefs were related to adherence. Three studies showed 
that “necessity beliefs”, defined as judgments of personal 
need for the treatment,12 were significantly related to 
increased adherence.35,66,67 The adherence estimator measures T
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Barriers and facilitators of HT adherence
perceived need for medication, concerns and affordability 
and categorizes people as low, medium and high risk for 
nonadherence. Women who were high risk were more likely 
to report being nonadherent.42 Negative and positive emotions 
regarding therapy were related to decreased and increased 
adherence, respectively,35,68 and perceived importance of 
therapy was related to increased adherence.61 Karmakar69 
found that coping appraisal, defined as the effectiveness of 
taking HT and self-efficacy in ability to take HT, minus the 
costs of taking HT, was associated with increased odds of 
adherence. Four studies found no effects of necessity beliefs 
on adherence.27,40,46,68 These four studies had small sample sizes 
and may have lacked power to find a significant effect. How-
ever, where effect sizes were given, they were relatively small. 
Three studies found a positive relationship between perceived 
self-efficacy for medication taking and adherence.27,29,69
Variables relating to patient–physician relationship 
tended to be associated with adherence. Patient–physician 
relationship quality,35 value of doctor’s opinion,61 frequency 
of physician communication,67 and self-efficacy in patient–
physician communication27 were positively associated with 
adherence. However, several of these were only tested in 
univariate analysis and in single studies.
Persistence
Having a neutral or negative decisional balance score, ie, 
believing that the benefits of the treatment do not outweigh the 
harms, was associated with three times lower odds of persis-
tence within the first 2 years of therapy.26 A 5-year follow-up 
study supported this relationship but with a smaller effect 
size.25 Positive and negative emotions regarding HT were 
associated with increased/decreased odds of adherence.35
Results for patient–physician relationship were mixed. 
Two studies found that perceptions of better physician 
communication were associated with increased odds of 
persistence,50,64 but three studies found no significant effects. 
However, one of these effects was nearing significance.25 
Being involved in decisions and discussing HT with a doctor 
were found to have no significant effects on persistence in 
two studies and a positive effect in one study.48 However, 
being able to ask questions and understanding information,10 
self-efficacy in patient–physician interaction,50 and receiving 
the right amount of support48 were significantly related to 
increased persistence.
Two studies showed that no longer fearing cancer recur-
rence was associated with an increased risk of treatment 
interruption,10,55 but this did not remain significant in multi-
variate analysis.55 Three studies found that women reporting 
low levels of social support were less likely to persist with 
treatment.10,64,70
Discussion
This article reviewed the evidence for clinical, demographic 
and psychosocial predictors of HT adherence and persistence 
to present a holistic view of the evidence base. Empirical 
interest in this area is growing, and this review builds upon 
previous reviews by incorporating 27 new studies. One 
previous review concluded that social support, patient-cen-
tered interactions, anxiety and beliefs were related to nonad-
herence/nonpersistence.18 While this current review supports 
some of these findings, new research has questioned whether 
anxiety is related to nonadherence. Cahir et al17 found that 
side effects and follow-up care with a GP (vs oncologist) 
was negatively associated with persistence and the number 
of medications was positively associated with persistence. 
This review supported the previous findings that receiving 
Table 5 Relationship between side effects and HT adherence/
persistence
Variable Number of studies showing 
positive/negative effect 
Adherence Persistence
Any side effects 2× negative27*,29
3× no effects 
3× negative35*,46*,47
2× no effects
Severe side effects 0 2× negative25,48
1× no effects
Overall hormone/
menopause related
0 1× positive51*
2× negative10,50
Hot flushes/vasomotor 
symptoms/sweating 
5× no effects 1× positive48
1× negative49
1× no effects 
Overall sleep/fatigue related 2× no effects 2× no effects
Gynecological symptoms 1× positive42*
2× negative40*,41*
3× no effects
1× positive51*
2× no effects 
Sex-related symptoms 4× no effects 2× no effects 
Joint aches and pains/
osteoporosis 
2× negative40*,41*
2× no effects
2× no effects 
weight concerns 2× negative40*,41
1× no effects
1× no effects
incontinence/bladder control 3× no effects 1× no effects
Hair thinning/loss 0 1× positive51*
Headaches 0 1× negative51*
Loss of appetite 0 1× negative51*
Gastrointestinal symptoms 2× no effects 0
Cognitive symptoms 2× negative40*,41*
1× no effects 
0
Notes: individual symptoms that were only tested in one study and were not 
significant are not listed (shortness of breath, eyesight changes, breast sensitivity, 
fractures/broken bones and retaining water). *The effect was not significant in 
multivariate analysis or was not tested in multivariate analysis.
Abbreviation: HT, hormone therapy.
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care from an oncologist was associated with increased persis-
tence but found mixed results for the number of medications 
and side effects. This review also highlighted new factors, 
such as younger age and hospitalizations, and moved beyond 
these findings to identify modifiable factors, such as self-
efficacy for medication taking.
Researchers and clinicians often assume that side effects, 
especially menopausal symptoms, trigger nonadherence.71,72 
Although some studies found a relationship between side 
effects and adherence/persistence, the relationship was not 
always supported.73 However, studies investigating the 
effects of hot flushes were low to moderate quality, so further 
high-quality research is needed. Several studies found that 
nonadherent or nonpersistent women reported fewer side 
effects, possibly as a result of not taking the medication. 
Future research should therefore measure adherence and 
side effects at several time points to see how the relationship 
changes across time. Qualitative research has shown that 
some women would not discontinue HT regardless of its 
side effects (Moon Z, Moss-Morris R, Hunter M, Hughes L., 
 unpublished data, 2017), which may account for the inconsis-
tent relationship between side effects and adherence.
Being treated by specialists rather than a general practi-
tioner increased persistence. These physicians may provide 
more specialized and informed care,43 leading to women 
being more educated and having positive treatment beliefs, 
although this was not measured directly. An intervention 
focusing on knowledge and beliefs may support women who 
did not receive this from their physician. This is supported 
by the studies showing that medication beliefs are related to 
adherence levels.26,35 Furthermore, several studies showed 
that variables relating to the patient–physician relationship 
and physician communication were associated with increased 
odds of adherence. These results suggest that training primary 
care physicians to provide more specialized care could 
improve adherence rates.
Some evidence suggested that women whose insurance 
data indicated nonadherence or nonpersistence over 1–5 years 
were more likely to have been hospitalized over the same 
period. These women may have not taken their medication 
while in hospital, but as no data were provided for adher-
ence levels during the hospitalization, no strong conclusions 
can be made. There was relatively consistent evidence from 
moderate- to high-quality studies, suggesting that younger 
women had lower odds of adherence and slightly less con-
sistent evidence for a relationship between younger age and 
nonpersistence. This is in line with previous reviews into 
adherence in cancer and other illnesses.74,75 Young women 
may not take HT due to issues around early menopause or 
fertility24 as HT precludes conception. In addition, young 
women do not adjust as well to a cancer diagnosis, which may 
affect adherence.54,76 Results were mixed for the relationship 
between older age and adherence or persistence.
In terms of modifiable factors, three studies found that 
women who reported few sources of social support were 
more likely to discontinue treatment. The importance of 
social support in maintaining adherence has been highlighted 
previously,77,78 but social support was only found to relate 
to persistence in this review. Discussing the importance of 
maintaining good social networks and disclosure of cancer 
status may increase levels of perceived social support. Several 
studies have shown promise for the effectiveness of social 
support interventions.79,80 Self-efficacy for medication taking, 
defined as the patient’s confidence in their ability to take the 
medication as prescribed, was associated with increased odds 
of self-reported adherence.27 Self-efficacy for medication 
taking could be modified by teaching patients strategies to 
remember to take their medication and helping patients to 
overcome other practical barriers through modeling, goal set-
ting, or confidence building. Similar interventions have been 
successful at improving self-efficacy for physical activity and 
dietary behaviors.81,82
Patients who held stronger beliefs regarding how 
efficacious, necessary, important and affordable HT is were 
more likely to have higher self-reported adherence, as were 
women who reported more positive emotions around HT. 
In addition, women who felt that the risks of the treatment 
outweighed the benefits were three times more likely to dis-
continue. This relationship between beliefs and adherence 
is supported by the Necessity Concerns Framework (NCF) 
and has been demonstrated previously.83,84 The NCF suggests 
that adherence is related to holding high perceptions of the 
necessity of the medication and low concerns. These beliefs 
are often shown to be more powerful predictors of adher-
ence than clinical or sociodemographic characteristics and 
have been successfully modified through intervention.35,83,85 
However, the studies investigating beliefs in this review were 
low- to moderate-quality cross-sectional studies and some 
used unvalidated measures. In addition, while medication 
concerns are often found to be predictive of adherence,83 the 
majority of studies found nonsignificant results. This suggests 
that it may be more important to measure how people weigh 
up their concerns against their necessity beliefs.
The variability between studies may reflect the heteroge-
neous populations studied. There were discrepancies in geo-
graphic location, health care systems and clinical characteristics. 
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Furthermore, while several studies recruited patients at the ini-
tiation of treatment, many studies did not specify the stage of 
treatment. Research has shown that determinants of adherence 
vary significantly over time.10 Therefore, future research 
should try to recruit patients at the same time point, explicitly 
state participants’ stage of treatment and follow them over the 
duration of the prescription period.
The results from this review suggest that there are no 
strong predictors of HT adherence or persistence. Reviewing 
high-quality studies in isolation (n=22) reflected this pattern 
of inconsistent results. However, the high-quality studies did 
support the trend of higher rates of discontinuation in older 
women and lower adherence in black women, suggesting a 
need to further investigate these relationships. The majority 
of predictors investigated, such as age, are not amenable 
to change through intervention. Future research is needed 
to identify psychosocial factors that have been shown to 
impact on adherence in other conditions. For example, illness 
perceptions have been shown to be predictive of adherence 
in other illnesses but have not been investigated fully in HT 
adherence.12,86 This review identified one study investigat-
ing illness perceptions, which found that coherence beliefs, 
ie, patients’ ratings of their understanding of their breast 
cancer, were the only significant predictors of nonadherence 
in multivariate analysis.46 Self-efficacy for taking medica-
tion, social support and medication beliefs provide potential 
targets for intervention. However, higher quality research is 
needed in order to clarify the relationship between medica-
tion beliefs and adherence. Interventions could also focus 
on training clinicians and general practitioners to improve 
patient–physician communication.
There are several limitations to this review. It was not 
possible to conduct a meta-analysis due to significant het-
erogeneity between studies. This heterogeneity also makes 
it difficult to compare across studies and make conclusions 
based on significant predictors of nonadherence. Although 
a wide search was conducted and attempts were made to 
identify gray literature, some relevant articles may not have 
been identified. The conclusions are limited by the method-
ological quality of the included studies. There was a risk of 
selection bias in some studies, which means a subset of the 
population who are potentially more at risk of nonadherence 
may not be included. Sixteen studies were cross-sectional 
which limits assumptions about causality. Two studies used 
MEMS to measure adherence and found very high levels, 
most likely due to the Hawthorne effect where adher-
ence increases because patients know that they are being 
monitored.87 The most common measurement of adherence 
and persistence was prescription refill, which is known to be 
the most objective measure.88 However, this measurement 
is still flawed, as we do not know if the patient actually took 
their medication. Several studies used physician ratings, 
which are likely to grossly overestimate adherence levels.89 
Self-report measures are also susceptible to overreporting due 
to social desirability. Four studies overcame these limitations 
somewhat by using validated questionnaires.
There are several reasons that a patient may be recom-
mended by their physician to discontinue treatment, such 
as recurrence and contraindications. These patients should 
not be classified in the same way as women who choose 
to discontinue HT and should be removed from analysis. 
Around a third of studies attempted to adjust for this by 
removing women who had a recurrence or who died. Seven 
studies did not allow patients to switch medications and 
still be considered persistent, and 13 studies were unclear 
as to whether they allowed this. Furthermore, only a few 
studies have clearly distinguished between nonadherence 
and nonpersistence and provided independent figures for 
both. Without this information, it is not possible to determine 
the full medication-taking behavior of these patients and, 
therefore, the clinical impact. The behaviors and outcomes 
of completely stopping treatment and occasionally skipping 
doses are different, so it is important to understand these as 
independent with unique predictors. Future research needs 
to be clear about how nonadherence rates are classified and 
ideally to provide independent rates for nonadherence and 
nonpersistence.
Conclusion
Understanding the determinants of nonadherence is essential 
when designing interventions to improve HT adherence and 
ensuring that patients realize the full benefits of HT. The main 
conclusions that can be drawn from this review are that while 
clinical and demographic factors may be useful in order to 
identify women at risk of nonadherence, extensive research 
has not yet identified any consistent predictors. There was 
some evidence that increased adherence was related to 
younger age, fewer hospitalizations and better patient–physi-
cian relationship, but these relationships were not always sup-
ported. Persistence was related to receiving treatment from 
a specialist. In terms of modifiable factors, there was some 
evidence to suggest that beliefs about HT, social support and 
self-efficacy for taking medication were related to adherence 
and persistence. In order to guide effective interventions 
to improve HT adherence and persistence, future research 
should focus on these factors and on identifying additional 
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potentially modifiable factors, which have been shown to be 
related to adherence in other illnesses.13 Furthermore, strate-
gies to improve patient–physician relationship and service 
delivery should be investigated.
Acknowledgment
This study was supported by Breast Cancer Now (for-
mally Breast Cancer Campaign) under grant number: 
2013NovPhD201.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Breast Cancer Statistics [webpage on the Internet]. Cancer Research 
UK Web Site; 2016. Available from: http://www.cancerresearchuk.
org/health-professional/cancer-statistics/statistics-by-cancer-type/
breast-cancer. Accessed October 10, 2016.
 2. Gray RG, Rea D, Handley K, et al. ATTom: long-term effects of con-
tinuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 
6,953 women with early breast cancer. J Clin Oncol. 2013;18(31):5.
 3. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early 
breast cancer: an overview of the randomised trials. Early Breast Cancer 
Trialists’ Collaborative Group. Lancet. 1998;351(9114):1451–1467.
 4. Barron TI, Cahir C, Sharp L, Bennett K. A nested case-control study of 
adjuvant hormonal therapy persistence and compliance, and early breast 
cancer recurrence in women with stage I–III breast cancer. Br J Cancer. 
2013;109(6):1513–1521.
 5. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-
adherence to adjuvant hormonal therapy are associated with increased 
mortality in women with breast cancer. Breast Cancer Res Treat. 2011; 
126(2):529–537.
 6. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. 
Cohort study of adherence to adjuvant endocrine therapy, breast cancer 
recurrence and mortality. Br J Cancer. 2013;108(7):1515–1524.
 7. Huiart L, Bouhnik A-D, Rey D, et al. Complementary or alternative 
medicine as possible determinant of decreased persistence to aromatase 
inhibitor therapy among older women with non-metastatic breast cancer. 
PLoS One. 2013;8(12):e81677.
 8. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and 
nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-
stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–4128.
 9. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant 
tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 
2003;21(4):602–606.
 10. Cluze C, Rey D, Huiart L, et al. Adjuvant endocrine therapy with 
tamoxifen in young women with breast cancer: determinants of inter-
ruptions vary over time. Ann Oncol. 2012;23(4):882–890.
 11. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinu-
ation among older women with estrogen receptor-positive breast cancer. 
J Clin Oncol. 2008;26(4):549–555.
 12. Horne R, Weinman J. Self-regulation and self-management in asthma: 
exploring the role of illness perceptions and treatment beliefs in 
explaining non-adherence to preventer medication. Psychol Health. 
2002;17(1):17–32.
 13. Chilcot J, Wellsted D, Farrington K. Illness representations are 
associated with fluid nonadherence among hemodialysis patients. 
J Psychosom Res. 2010;68(2):203–212.
 14. Goulding L, Furze G, Birks Y. Randomized controlled trials of inter-
ventions to change maladaptive illness beliefs in people with coronary 
heart disease: systematic review. J Adv Nurs. 2010;66(5):946–961.
 15. Petrie KJ, Perry K, Broadbent E, Weinman J. A text message programme 
designed to modify patients’ illness and treatment beliefs improves 
self-reported adherence to asthma preventer medication. Br J Health 
Psychol. 2012;17(1):74–84.
 16. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, 
Vernon SW. Adherence to adjuvant hormonal therapy among breast 
cancer survivors in clinical practice: a systematic review. Breast Cancer 
Res Treat. 2012;134(2):459–478.
 17. Cahir C, Guinan E, Dombrowski SU, Sharp L, Bennett K. Identify-
ing the determinants of adjuvant hormonal therapy medication taking 
behaviour in women with stages I–III breast cancer: a systematic review 
and meta-analysis. Patient Educ Couns. Epub 2015 May 30.
 18. Van Liew JR, Christensen AJ, de Moor JS. Psychosocial factors in 
adjuvant hormone therapy for breast cancer: an emerging context for 
adherence research. J Cancer Surviv. 2014;8(3):521–531.
 19. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement 
for reporting systematic reviews and meta-analyses of studies that 
evaluate healthcare interventions: explanation and elaboration. BMJ. 
2009;339:b2700.
 20. McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ. 
The value of high adherence to tamoxifen in women with breast 
cancer: a community-based cohort study. Br J Cancer. 2013;109(5): 
1172–1180.
 21. Pasma A, van’t Spijker A, Hazes JMW, Busschbach JJV, Luime JJ. 
Factors associated with adherence to pharmaceutical treatment for rheu-
matoid arthritis patients: a systematic review. Semin Arthritis Rheum. 
2013;43(1):18–28.
 22. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and 
susceptibility to bias in observational studies in epidemiology: a sys-
tematic review and annotated bibliography. Int J Epidemiol. 2007;36(3): 
666–676.
 23. Brito C, Portela MC, de Vasconcellos MTL. Adherence to hormone ther-
apy among women with breast cancer. BMC Cancer. 2014;14(1):397.
 24. Brito C, Portela MC, Leite de Vasconcellos MT. Factors associated 
to persistence with hormonal therapy in women with breast cancer. 
Rev Saude Publica. 2014;48(2):284–295.
 25. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to 
tamoxifen over the five-year course. Breast Cancer Res Treat. 2006; 
99(2):215–220.
 26. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient 
beliefs and tamoxifen discontinuance in older women with estrogen 
receptor-positive breast cancer. J Clin Oncol. 2004;22(16):3309–3315.
 27. Kimmick G, Edmond SN, Bosworth HB, et al. Medication taking 
behaviors among breast cancer patients on adjuvant endocrine therapy. 
Breast. 2015;24(5):630–636.
 28. Tinari N, Fanizza C, Romero M, et al. Identification of subgroups of early 
breast cancer patients at high risk of nonadherence to adjuvant hormone 
therapy: results of an Italian survey. Clin Breast Cancer. 2015;15(2): 
e131–e137.
 29. Wouters H, Stiggelbout AM, Bouvy ML, et al. Endocrine therapy for 
breast cancer: assessing an array of women’s treatment experiences 
and perceptions, their perceived self-efficacy and nonadherence. 
Clin Breast Cancer. 2014;14(6):460–467.e2.
 30. Hershman DL, Tsui J, Meyer J, et al. The change from brand-name 
to generic aromatase inhibitors and hormone therapy adherence for 
early-stage breast cancer. J Natl Cancer Inst. 2014;106(11):dju319.
 31. Hershman DL, Tsui J, Wright JD, Coromilas EJ, Tsai WY, Neugut AI. 
Household net worth, racial disparities, and hormonal therapy adher-
ence among women with early-stage breast cancer. J Clin Oncol. 
2015;33(9):1053–1059.
 32. Neugut AI, Subar M, Wilde ET, et al. Association between prescrip-
tion co-payment amount and compliance with adjuvant hormonal 
therapy in women with early-stage breast cancer. J Clin Oncol. 2011; 
29(18):2534–2542.
 33. Lee HS, Lee JY, Ah YM, et al. Low adherence to upfront and extended 
adjuvant letrozole therapy among early breast cancer patients in a 
clinical practice setting. Oncology. 2014;86(5–6):340–349.
Patient Preference and Adherence 2017:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
321
Barriers and facilitators of HT adherence
 34. Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibi-
tors among commercially insured women with breast cancer. Breast 
Cancer Res Treat. 2011;125(1):191–200.
 35. Stanton AL, Petrie KJ, Partridge AH. Contributors to nonadherence 
and nonpersistence with endocrine therapy in breast cancer survivors 
recruited from an online research registry. Breast Cancer Res Treat. 2014; 
145(2):525–534.
 36. Trabulsi N, Reidel KE, Winslade NE, et al. Adherence to anti-estrogen 
therapy in seniors with breast cancer: how well are we doing? Breast J. 
2014;20(6):632–638.
 37. Wigertz A, Ahlgren J, Holmqvist M, et al. Adherence and discontinua-
tion of adjuvant hormonal therapy in breast cancer patients: a population-
based study. Breast Cancer Res Treat. 2012;133(1):367–373.
 38. Font R, Espinas JA, Gil-Gil M, et al. Prescription refill, patient self-
report and physician report in assessing adherence to oral endocrine 
therapy in early breast cancer patients: a retrospective cohort study in 
Catalonia, Spain. Br J Cancer. 2012;107(8):1249–1256.
 39. Hsieh K-P, Chen L-C, Cheung K-L, Yang Y-H. Risks of nonadherence 
to hormone therapy in Asian women with breast cancer. Kaohsiung J 
Med Sci. 2015;31(6):328–334.
 40. Bender CM, Gentry AL, Brufsky AM, et al. Influence of patient and 
treatment factors on adherence to adjuvant endocrine therapy in breast 
cancer. Oncol Nurs Forum. 2014;41(3):274–285.
 41. Wickersham KE, Sereika SM, Bender CM. Pretreatment predictors 
of short-term nonadherence to oral hormonal therapy for women with 
breast cancer. Nurs Res. 2013;62(4):243–251.
 42. Schover LR, Baum GP, Fuson LA, Brewster A, Melhem-Bertrandt A. 
Sexual problems during the first 2 years of adjuvant treatment with 
aromatase inhibitors. J Sex Med. 2014;11(12):3102–3111.
 43. Hadji P, Ziller V, Kyvernitakis J, et al. Persistence in patients with breast 
cancer treated with tamoxifen or aromatase inhibitors: a retrospective 
database analysis. Breast Cancer Res Treat. 2013;138(1):185–191.
 44. Kostev K, Waehlert L, Jockwig A, Jockwig B, Hadji P. Physicians’ influ-
ence on breast cancer patient compliance. Ger Med Sci. 2014;12:Doc03.
 45. Kostev K, May U, Hog D, et al. Adherence in tamoxifen therapy after 
conversion to a rebate pharmaceutical in breast cancer patients in 
Germany. Int J Clin Pharmacol Ther. 2013;51(12):969–975.
 46. Corter AL. Treatment Side Effects and Nonadherence among Women 
Taking Adjuvant Endocrine Therapy for Breast Cancer: The Role of 
Psychological Factors [PhD thesis]. Auckland: The University of 
Auckland; 2013.
 47. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of 
use, side effects, and discontinuation in older women. J Clin Oncol. 
2001;19(2):322–328.
 48. Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM. Patient 
centered experiences in breast cancer – predicting long-term adherence 
to tamoxifen use. Med Care. 2007;45(5):431–439.
 49. Kemp A, Preen DB, Saunders C, et al. Early discontinuation of endo-
crine therapy for breast cancer: who is at risk in clinical practice? 
Springerplus. 2014;3:282.
 50. Liu Y, Malin JL, Diamant AL, Thind A, Maly RC. Adherence to adjuvant 
hormone therapy in low-income women with breast cancer: the role of 
provider-patient communication. Breast Cancer Res Treat. 2013;137(3): 
829–836.
 51. Aiello Bowles EJ, Boudreau DM, Chubak J, et al. Patient-reported 
discontinuation of endocrine therapy and related adverse effects among 
women with early-stage breast cancer. J Oncol Pract. 2012;8(6): 
e149–e157.
 52. Riley GF, Warren JL, Harlan LC, Blackwell SA. Endocrine therapy 
use among elderly hormone receptor-positive breast cancer patients 
enrolled in Medicare Part D. Medicare Medicaid Res Rev. 2011;1(4).
 53. Guth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM. 
Compliance and persistence of endocrine adjuvant breast cancer 
therapy. Breast Cancer Res Treat. 2012;131(2):491–499.
 54. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discon-
tinuation of tamoxifen: a lesson for oncologists. Cancer. 2007;109(5): 
832–839.
 55. Friese CR, Pini TM, Li Y, et al. Adjuvant endocrine therapy initiation 
and persistence in a diverse sample of patients with breast cancer. Breast 
Cancer Res Treat. 2013;138(3):931–939.
 56. Krotneva SP, Ramjaun A, Reidel KE, et al. Use of hormonal therapy 
in senior breast cancer patients treated with or without radiotherapy. 
Curr Oncol. 2014;21(1):e105–e115.
 57. Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK. Five-year patterns 
of adjuvant hormonal therapy use, persistence, and adherence among 
insured women with early-stage breast cancer. Breast Cancer Res Treat. 
2011;130(2):681–689.
 58. Wu J, Stafkey-Mailey D, Bennett CL. Long-term adherence to hor-
mone therapy in medicaid-enrolled women with breast cancer. Health 
Outcomes Res Med. 2012;3(4):e195–e203.
 59. Seneviratne S, Campbell I, Scott N, et al. Adherence to adjuvant 
endocrine therapy: is it a factor for ethnic differences in breast cancer 
outcomes in New Zealand? Breast. 2015;24(1):62–67.
 60. Schmidt N, Kostev K, Jockwig A, Kyvernitakis I, Albert US, Hadji P. 
Treatment persistence evaluation of tamoxifen and aromatase inhibi-
tors in breast cancer patients in early and late stage disease. Int J Clin 
Pharmacol Ther. 2014;52(11):933–939.
 61. Bhatta SS, Hou N, Moton ZN, et al. Factors associated with compliance 
to adjuvant hormone therapy in Black and White women with breast 
cancer. Springerplus. 2013;2:356.
 62. He W, Fang F, Varnum C, Eriksson M, Hall P, Czene K. Predictors 
of discontinuation of adjuvant hormone therapy in patients with breast 
cancer. J Clin Oncol. 2015;33(20):2262–2269.
 63. van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, 
Nieuwenhuijzen GA, Coebergh JW, Herings RM. Half of breast 
cancer patients discontinue tamoxifen and any endocrine treatment 
before the end of the recommended treatment period of 5 years: a 
population-based analysis. Breast Cancer Res Treat. 2010;122(3): 
843–851.
 64. Sheppard VB, Faul LA, Luta G, et al. Frailty and adherence to adjuvant 
hormonal therapy in older women with breast cancer: CALGB protocol 
369901. J Clin Oncol. 2014;32(22):2318–2327.
 65. Llarena NC, Estevez SL, Tucker SL, Jeruss JS. Impact of fertility con-
cerns on tamoxifen initiation and persistence. J Natl Cancer Inst. 2015; 
107(10):djv202.
 66. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among 
breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59(1): 
97–102.
 67. Jacob Arriola KR, Mason TA, Bannon KA, et al. Modifiable risk factors 
for adherence to adjuvant endocrine therapy among breast cancer 
patients. Patient Educ Couns. 2014;95(1):98–103.
 68. Walker HE, Rosenberg SM, Stanton AL, Petrie KJ, Partridge AH. 
Perceptions, attributions, and emotions toward endocrine therapy in 
young women with breast cancer. J Adolesc Young Adult Oncol. 2016; 
5(1):16–23.
 69. Karmakar M. Predicting Adherence to Aromatase Inhibitor Therapy 
in Patients with Breast Cancer Using Protection Motivation Theory 
[PhD thesis]. Toledo: The University of Toledo; 2013.
 70. Huiart L, Bouhnik AD, Rey D, et al. Early discontinuation of 
tamoxifen intake in younger women with breast cancer: is it time 
to rethink the way it is prescribed? Eur J Cancer. 2012;48(13): 
1939–1946.
 71. Gotay C, Dunn J. Adherence to long-term adjuvant hormonal therapy 
for breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2011; 
11(6):709–715.
 72. Wheeler SB, Roberts MC, Bloom D, et al. Oncology providers’ per-
spectives on endocrine therapy prescribing and management. Patient 
Prefer Adherence. 2016;10:2007–2019.
 73. Hogan BE, Linden W, Najarian B. Social support interventions: do they 
work? Clin Psychol Rev. 2002;22(3):383–442.
 74. Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A. 
Determinants and associated factors influencing medication adherence 
and persistence to oral anticancer drugs: a systematic review. Cancer 
Treat Rev. 2013;39(6):610–621.
Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal that focuses on the growing importance of patient 
 preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and their 
role in  developing new therapeutic modalities and compounds to optimize 
clinical  outcomes for existing disease states are major areas of interest for 
the  journal. This journal has been accepted for indexing on PubMed Central. 
The  manuscript management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit http://www.
dovepress.com/testimonials.php to read real quotes from published authors.
Patient Preference and Adherence 2017:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
322
Moon et al
 75. Barr R, Somers SC, Speizer FE, Camargo CA Jr; National Asthma 
Education and Prevention Program (NAEPP). Patient factors and 
medication guideline adherence among older women with asthma. Arch 
Inten Med. 2002;162(15):1761–1768.
 76. Compas BE, Stoll MF, Thomsen AH, Oppedisano G, Epping-Jordan JE, 
Krag DN. Adjustment to breast cancer: age-related differences in 
coping and emotional distress. Breast Cancer Res Treat. 1999;54(3): 
195–203.
 77. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with 
oral antineoplastic agents. J Natl Cancer Inst. 2002;94(9):652–661.
 78. Knodel J, Kespichayawattana J, Saengtienchai C, Wiwatwanich S. 
The role of parents and family members in ART treatment adherence: 
evidence from Thailand. Res Aging. 2010;32(1):19–39.
 79. Barrera M, Glasgow RE, McKay HG, Boles SM, Feil EG. Do 
internet-based support interventions change perceptions of social 
support?: an experimental trial of approaches for supporting diabetes 
self-management. Am J Community Psychol. 2002;30(5):637–654.
 80. Czechura T, Winchester DJ, Pesce C, Barrera E, Winchester DP, Yao K. 
Impact of bilateral versus unilateral mastectomy on short term outcome 
and adjuvant therapy. Ann Surg Oncol. 2013;1:S49.
 81. Ashford S, Edmunds J, French DP. What is the best way to change 
self-efficacy to promote lifestyle and recreational physical activity? 
A systematic review with meta-analysis. Br J Health Psychol. 2010; 
15(2):265–288.
 82. Prestwich A, Kellar I, Parker R, et al. How can self-efficacy be 
increased? Meta-analysis of dietary interventions. Health Psychol Rev. 
2014;8(3):270–285.
 83. Horne R, Weinman J. Patients’ beliefs about prescribed medicines 
and their role in adherence to treatment in chronic physical illness. 
J Psychosom Res. 1999;47(6):555–567.
 84. Clatworthy J, Bowskill R, Parham R, Rank T, Scott J, Horne R. 
Understanding medication non-adherence in bipolar disorders using 
a Necessity-Concerns Framework. J Affect Disord. 2009;116(1–2): 
51–55.
 85. O’Carroll RE, Chambers JA, Dennis M, Sudlow C, Johnston M. Improv-
ing adherence to medication in stroke survivors: a pilot randomised 
controlled trial. Ann Behav Med. 2013;46(3):358–368.
 86. Byer B, Myers LB. Psychological correlates of adherence to medication 
in asthma. Psychol Health Med. 2000;5(4):389–393.
 87. Wetzels GE, Nelemans PJ, Schouten JS, van Wijk BL, Prins MH. All that 
glisters is not gold: a comparison of electronic monitoring versus filled 
prescriptions – an observational study. BMC Health Serv Res. 2006;6:8.
 88. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with 
oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56–66.
 89. Oberguggenberger AS, Sztankay M, Beer B, et al. Adherence evaluation 
of endocrine treatment in breast cancer: methodological aspects. BMC 
Cancer. 2012;12:474.
 90. Cheung WY, Lai EC-C, Ruan JY, Chang JT, Setoguchi S. Comparative 
adherence to oral hormonal agents in older women with breast cancer. 
Breast Cancer Res Treat. 2015;152(2):419–427.
 91. Danilak M, Chambers CR. Adherence to adjuvant endocrine therapy 
in women with breast cancer. J Oncol Pharm Pract. 2013;19(2): 
105–110.
 92. Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. 
Adjuvant hormonal therapy use among insured, low-income women 
with breast cancer. J Clin Oncol. 2009;27(21):3445–3451.
 93. Kuba S, Ishida M, Shigechi T, et al. Persistence and discontinuation 
of adjuvant endocrine therapy in Japanese women with breast cancer. 
Breast Cancer. 2016;23(1):128–133.
 94. Livaudais JC, LaCroix A, Chlebowski RT, et al. Racial/ethnic differ-
ences in use and duration of adjuvant hormonal therapy for breast cancer 
in the women’s health initiative. Cancer Epidemiol Biomarkers Prev. 
2012;22:365–373.
 95. Simon R, Latreille J, Matte C, Desjardins P, Bergeron E. Adherence to 
adjuvant endocrine therapy in estrogen receptor-positive breast cancer 
patients with regular follow-up. Can J Surg. 2014;57(1):26–32.
 96. Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine 
therapy in postmenopausal women with breast cancer. Ann Oncol. 
2009;20(3):431–436.
 97. Zeeneldin AA, Gaber AA, Taha FM. Does fasting during Ramadan trig-
ger non-adherence to oral hormonal therapy in breast cancer patients? 
J Egypt Natl Canc Inst. 2012;24(3):133–137.
